Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 21 of 24, showing 5 Applications out of 119 total, starting on record 101, ending on 105

# Protocol No Study Title Investigator(s) & Site(s)

101.

ECCT/24/04/03   SMAART-MAP trial
    Severe Malaria A Research and Trials consortium - Multisite Adaptive Platform trial   
Principal Investigator(s)
1. Prof Kathryn Maitland Maitland
Site(s) in Kenya
Kilifi County Hospital
 
View

102.

ECCT/20/11/02   IAVI C100
    Safety and Pharmacokinetics of the Combination Broadly Neutralizing  Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and   African Adults (IAVI C100)   
Principal Investigator(s)
1. Nelly Mugo
Site(s) in Kenya
1. Partners in Health Research and Development (PHRD) – CCR-KEMRI (Kiambu county)
2. Kenya AIDS Vaccine Initiative- Institute of Clinical Research (KAVI-ICR) (Nairobi City county)
 
View

103.

ECCT/16/04/01   HVTN 703/HPTN 081 Protocol A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection
    HVTN 703/HPTN 081   A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection   
Principal Investigator(s)
1. Dr. Victor Akelo Akelo
Site(s) in Kenya
KISUMU CRS
 
View

104.

ECCT/18/01/01   Mal 094
    Efficacy, safety and immunogenicity study of GSK Biologicals’ candidate malaria vaccine (SB257049) evaluating schedules with or without fractional doses, early Dose 4 and yearly doses, in children 5-17 months of age.   
Principal Investigator(s)
1. Aaron Samuels
2. Simon Kariuki
Site(s) in Kenya
1. Siaya County Referral hospital (Siaya county)
2. Ngiya Health Center (Siaya county)
3. Kogelo Health Center (Siaya county)
4. Tingwangi (Siaya county)
5. Mulaha (Siaya county)
6. Nyathengo (Siaya county)
7. Bal Olengo (Siaya county)
 
View

105.

ECCT/16/05/01   A5338
    A5338   An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among   Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz   (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and   Tuberculosis (TB)   
Principal Investigator(s)
1. David Schnabel
Site(s) in Kenya
KISUMU CRS
 
View